Accessibility Menu
Kamada logo

Kamada(NASDAQ) KMDA

Market Cap$423.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)-16%
5 Year+39%
1 Year+5%
1 Month-2%
$7.21
-1.77%
-0.13Today
Kamada last closing stock price
MetricPriceDate
Last closeUSD 7.342026-08-04
Kamada stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.97%USD 7.062026-07-28
1 month-2.13%USD 7.502026-07-02
3 month-11.35%USD 8.282026-05-06
Year to date+7.12%USD 6.852025-12-31
1 year+5.18%USD 6.982025-08-04
3 year+45.68%USD 5.042023-08-04
5 year+39.16%USD 5.272021-08-05
Since inception-15.9%USD 8.732008-06-02

Kamada Financials at a Glance

Market Cap

$423.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$181.68M

Net Income (TTM)

$20.37M

EPS (TTM)

$0.35

P/E Ratio

20.76

Dividend

$0.25

Beta (Volatility)

0.71 (Low)

Price

$7.21

Volume

83,734.631

Open

$7.25

Previous Close

$7.34

Daily Range

$7.17 - $7.33

52-Week Range

$6.50 - $9.35

Estimated Earnings Date

Aug 12, 2026

KMDA News

GettyImages-1218407610

Kamada Will Supply COVID-19 Treatment to Israel

Taylor CarmichaelOct 19, 2020
CV upclose

2 Coronavirus Treatment Stocks to Buy Right Now

George Budwell, PhDSep 9, 2020
Trump in news conference

What You Need to Know About the "Breakthrough" Coronavirus Therapy Heralded by President Trump

Keith SpeightsAug 25, 2020
blood plasma

Why ADMA Biologics, iBio, and Kamada Are Jumping Today

George Budwell, PhDAug 24, 2020
COVID-19 vial stock market

The 1 Promising Coronavirus Stock No One Knows About Yet

Mark PrvulovicJul 31, 2020
featured-transcript-logo

Kamada Ltd. (KMDA) Q1 2019 Earnings Call Transcript

Motley Fool TranscriptionMay 17, 2019

KMDA: Motley Fool Moneyball Superscore

64

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kamada

Kamada Ltd. is a biopharmaceutical firm specializing in the development, manufacturing, and distribution of protein therapeutics derived from human plasma. The company operates through two main segments: proprietary products and distribution of third-party pharmaceuticals.

Products and Services
  • KAMRAB/KEDRAB for rabies prevention
  • CYTOGAM for cytomegalovirus disease prevention
  • WINRHO SDF for immune thrombocytopenic purpura treatment
Growth Outlook
  • Revenue of $45.24 million in Q1 2026, showing consistent growth
  • Net income increased to $4.13 million in Q1 2026
  • Strong collaborations with major pharmaceutical companies enhance market reach
Financial Highlights
  • Trailing twelve months (TTM) revenue of $182.4 million
  • Net profit margin of 11.21% indicates solid profitability
  • Current ratio of 3.33 suggests strong liquidity position
Kamada Ltd. has established itself as a key player in the biopharmaceutical industry, focusing on innovative therapies that address critical health needs. The company's diverse product portfolio, including treatments for rabies, cytomegalovirus, and immune disorders, positions it well for future growth. Recent financial performance highlights a robust revenue stream and profitability, with a TTM revenue of $182.4 million and a net profit margin of 11.21%. The strong liquidity position, indicated by a current ratio of 3.33, further supports the company's operational stability. Strategic partnerships with leading pharmaceutical firms enhance Kamada's market presence and potential for expansion, making it an intriguing option for investors interested in the healthcare sector.
AI Generated • Jul 23, 2026

Industry

Biotechnology

Sector

Health Care

Employees

462

CEO

Amir London

Website

www.kamada.com

Headquarters

Rehovot, HM 7670402, IL

KMDA Financials

Key Financial Metrics (TTM)

Gross Margin

41.16%

Operating Margin

13.98%

Net Income Margin

11.21%

Return on Equity

7.73%

Return on Capital

9.35%

Return on Assets

5.32%

Earnings Yield

4.82%

Dividend Yield

3.41%

Payout Ratio

55.45%

Stock Overview

Market Cap

$423.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

57.69M

Volume

83.73K

Avg. Volume

44.31K

Financials (TTM)

Gross Profit

$74.77M

Operating Income

$25.39M

EBITDA

$38.26M

Operating Cash Flow

$25.96M

Capital Expenditure

-$9.43M

Free Cash Flow

$16.53M

Cash & ST Invst.

$73.15M

Total Debt

$11.64M

Kamada Performance Analysis

Kamada annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 129,339,00024.8%
20232023-12-31USD 142,519,00010.2%
20242024-12-31USD 160,953,00012.9%
20252025-12-31USD 180,460,00012.1%
Kamada sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-301.7%
Q32025-09-305.0%
Q42025-12-31-5.0%
Q12026-03-311.3%
Kamada annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.054.0%
20232023-12-31USD 0.15N/A
20242024-12-31USD 0.2562.1%
20252025-12-31USD 0.3538.4%
Kamada sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3085.7%
Q32025-09-30-30.8%
Q42025-12-31-34.4%
Q12026-03-3118.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$45.24M

+2.8%

Gross Profit

$19.12M

-7.9%

Gross Margin

42.25%

N/A

Market Cap

$423.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$916.62K

N/A

Employees

462

N/A

Net Income

$4.13M

+4.2%

EBITDA

$9.43M

-9.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$73.15M

-4.1%

Total Debt

$11.64M

+4.9%

Accounts Receivable

$40.65M

+19.9%

Inventory

$85.44M

+9.0%

Long Term Debt

$9.44M

+1.3%

Short Term Debt

$2.20M

+23.5%

Return on Assets

5.32%

N/A

Return on Invested Capital

7.86%

N/A

Free Cash Flow

-$1.26M

+36.2%

Operating Cash Flow

-$291.00K

+43.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EOLSEvolus, Inc.
$6.17+0.74%
AUNAAuna S.A.
$5.22+1.75%
RCKTRocket Pharmaceuticals, Inc.
$3.50+1.74%
XOMAXOMA Royalty Corp.
$40.17+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$109.67-0.12%
NVDANvidia
$220.94+0.04%
ONDSOndas
$8.90+0.00%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.83-0.03%

Questions About KMDA

What is the current price of Kamada?

Kamada is trading at $7.19 per share.

What is the 52-week range for Kamada?

Over the past 52 weeks, Kamada has traded between $6.50 and $9.35.

How much debt does Kamada have?

As of the most recent reporting period, Kamada reported total debt of $11.64M.

How much cash does Kamada have on hand?

Kamada reported $32.92M in cash and cash equivalents in its most recent financial results.

What is Kamada’s dividend yield?

Kamada currently has a dividend yield of 3.41%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services